BACKGROUND: The efficacy and safety of atorvastatin in children/adolescents aged 10-17 years with heterozygous familial hypercholesterolemia (HeFH) have been demonstrated in trials of up to 1 year in duration. However, the efficacy/safety of .1 year use of atorvastatin in children/adolescents with HeFH, including children from 6 years of age, has not been assessed.
Introduction
Elevated cholesterol levels in childhood are associated with an increased incidence of atherosclerosis in adulthood. 1, 2 The severity of atherosclerosis can be correlated to the extent and duration of hypercholesterolemia. 3 Familial hypercholesterolemia (FH) is a common inherited autosomal dominant disorder of lipoprotein metabolism characterized by reduced clearance of low-density lipoprotein cholesterol (LDL-C) from the circulation leading to elevations of LDL-C. 4, 5 In most cases (85%-90%), FH is caused by defects in the low-density lipoprotein-receptor (LDL-R) gene. Defects in the genes for apolipoprotein B (apoB) and proprotein convertase subtilisin/kexin type 9 account for about 5% and ,5% of cases, respectively. 4 Rarely, autosomal recessive hypercholesterolemia can cause FH. 6, 7 In most populations, heterozygous familial hypercholesterolemia (HeFH) affects w1 in 200-250 individuals. 8 FH is associated with increased morbidity of coronary heart disease and with premature death [8] [9] [10] [11] , and children with FH have greater carotid intima media thickness than their unaffected siblings. 12, 13 Early intervention with cholesterol-lowering treatment, primarily statins, has been shown to prevent early coronary heart disease. [14] [15] [16] The evidence base for the efficacy and safety of statins in children is growing. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] However, gaps in this evidence base remain. 29 For example, studies conducted with atorvastatin in children/adolescents with HeFH were up to 1 year in duration with the impact on growth/development evaluated at 26 weeks. 26 Furthermore, the 1-year study was conducted in children/adolescents of 10-17 years, 26 whereas statins are now considered in children with HeFH ,10 years. 5 This 3-year study enrolling w250 subjects aged 6-15 years with genetically confirmed HeFH was therefore conducted to characterize the longterm efficacy and safety of atorvastatin and to assess the impact of this medication on growth and development. Also, as part of this work, we examined the impact of atorvastatin treatment on endothelial function in the brachial arteries assessed by flow-mediated dilation (FMD). 30 This was an optional exploratory study to assess the potential for a change in the FMD to act as a surrogate biomarker for the efficacy of LDL-C lowering as previously shown in a study with simvastatin therapy in children and adolescents with FH. 31 
Methods

Standard protocol approvals, registrations, and patient consents
This open-label, multicenter, prospective study was conducted between March 30, 2009 and October 8, 2013 at 30 centers across 14 counties in compliance with the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practice guidelines. In addition, all local regulatory requirements were followed. The protocol and the informed consent documents were reviewed and approved by the institutional review boards and/or independent ethics committees at each participating center. Parents or legal guardians provided informed consent. The subject could also sign a written consent form, if they were able to do so. The exact processes and procedures for attaining assent and consent varied between countries. However, all country-specific guidelines were complied with.
Study population
Girls and boys aged 6-15 years with genetically confirmed HeFH (those girls and boys who had no prior record of genetically confirmed HeFH underwent genetic testing pre-randomization to confirm whether they had HeFH). DNA was extracted from saliva or from blood, and the 18 exons and flanking regions of the LDL-R gene and exon 26 of the apoB gene were sequenced using SANGER methodology. Samples were also tested for large deletions or insertions in the LDL-R gene, using Multiplex Ligasedependent Probe Amplification (MLPA) analysis (Details provided in Supplementary Material).
All those who did not have genetically confirmed HeFH were excluded. All patients also had to have an LDL-C of $4.0 mmol/L (154 mg/dL) for inclusion. Exclusion criteria included a history of active liver disease, hepatic dysfunction, or persistent elevations of serum transaminases .3! the upper limit of normal (ULN) or conditions likely to delay puberty. Pregnant or breastfeeding females, and females of childbearing potential not using adequate contraception, were excluded. Subjects with hypersensitivities to statins or receiving statin therapy within 4 weeks of randomization were excluded. However, a 4-week washout of lipid-lowering medication was permitted.
Study design
The doses of atorvastatin used in this study were based on the results of a study comparing the efficacy and safety of different starting doses of atorvastatin in adults with dyslipidemia 32 and earlier studies conducted in 6-17-yearold subjects. 21, 26 In total, 272 subjects with HeFH were stratified into 2 cohorts according to their Tanner stage (TS) (1 or $2) at screening. Subjects aged 6 to ,10 years (mostly TS 1) initiated therapy on atorvastatin 5 mg per day (a pediatric chewable formulation), and those aged 10 to 15 years (mostly TS $ 2) initiated treatment with atorvastatin 10 mg per day.
Subjects had their dose titrated based on an LDL-C target of ,3.35 mmol/L (,130 mg/dL). Doses were increased from 5 to 10 to 20 mg or 10 to 20 to 40 mg per day. Titrations above 40 mg per day were permitted after discussions with the study sponsor. Subjects initiating treatment on atorvastatin 10 mg per day were permitted to decrease their dose if their LDL-C decreased to ,2.59 mmol/L (100 mg/dL). Subjects with LDL-C ,2.59 mmol/L on the 5 mg dose were discontinued.
Atorvastatin was dispensed at visit 1 (day 0), and subjects were seen monthly until month 6 at which point they were seen every 6 months. TS assessments were made at screening and every 6 months.
Outcome assessments
The primary assessments were measures of growth and development (height, weight, body mass index [BMI], TS), efficacy (absolute and percentage change from baseline in LDL-C, total cholesterol [TC], triglycerides [TG], highdensity lipoprotein cholesterol [HDL-C], apo A-1, apoB), tolerability, and safety. An exploratory secondary efficacy endpoint was change from baseline in FMD in a subset of subjects (see Supplemental Information). Subjects were required to fast for $10 hours before the collection of samples for lipid assessments. The incidence, severity, and potential causal relationship of treatment-emergent adverse events (AEs) were monitored alongside abnormal laboratory findings. Hematology, blood chemistry, and urinalysis were also evaluated at screening and throughout the study. AEs were classified as mild (does not interfere with subject's usual function), moderate (interferes to some extent with subject's usual function), or severe (interferes significantly with subject's usual function).
Statistical analysis
The full analysis set, defined as all subjects who received $1 doses of the study drug, was included in all analyses. No imputations were used for missing values. Subjects were categorized by TS 1 or $2 for analyses of lipid endpoints and safety/tolerability, and also by age ,10 years and $10 years for some analyses. Height, weight, BMI and FMD were analyzed by gender. Analyses were performed using descriptive statistics. Demographic and baseline data were summarized as mean 6 standard deviation (SD) for continuous variables. The mean dose of atorvastatin was calculated as the average dose per subject weighted by duration on each dose and the unweighted average calculated regardless of the duration on each dose and the mean maximum dose. The percentage of subjects receiving 5, 10, 20, 40, or 80 mg atorvastatin as their maximum dose stratified by TS and age was calculated. The percentage of subjects who attained an LDL-C goal of ,3.35 mmol/L (,130 mg/dL) at each visit was also calculated.
Results
Study population
A total of 400 pediatric subjects were screened and 272 with a genetically confirmed diagnosis of HeFH were enrolled (87 subjects without a previously confirmed genetic diagnosis of HeFH were considered for genetic screening and 66 were screened of which 49 [74.2%] were confirmed positive for HeFH) ( Fig. 1 ). This study was conducted at 30 centers worldwide, and the methodologies for genetic testing and the manner in which this information was collated differed both between centers and the central laboratory used to screen the patients without confirmed FH. Therefore, unfortunately, it has not been possible to collate this information for patients across the study. One subject was assigned to study treatment, but not treated, due to a protocol violation. The 271 subjects treated comprised 139 children at TS 1 and 132 adolescents at TS $2.
Overall, 206 subjects (76.0%) completed the study with 65 (24%) discontinuing. In subjects at TS1, the most frequent cause of discontinuation was no longer being willing to participate in the study, whereas for subjects at TS $2, the most common reason for discontinuation was ''low LDL-C'' (defined as LDL-C ,2.59 mmol/L [100 mg/ dL] in subjects receiving atorvastatin 5 mg; 12 subjects). Unfortunately, in some cases, investigators were unaware that subjects initiating treatment on 10 mg per day could be down-titrated to 5 mg per day; this knowledge may have prevented some of these discontinuations.
The mean age of children at TS 1 at baseline was 8.5 years (SD 5 1.9), the majority were male (66.9%) and white (96.4%; Table 1 ). The adolescents at TS $2 at baseline had a mean age of 12.0 years (SD 5 1.7), the majority were female (59.8%) and white (98.5%). Overall, 27.3% of subjects were aged 6-8 years, and 51.7% were aged #10 years at baseline.
The mean weighted and mean maximum doses were similar in the subjects at TS 1 and $2, whereas mean doses were consistently higher in the subjects aged $10 years vs those aged ,10 years ( Fig. 2A ). Few subjects (18, 6.6%) received atorvastatin 80 mg during the study, and 12 subjects (8.6%) at TS 1 received this maximum dose ( Table 1 ).
Efficacy
There was very little difference in the mean percentage changes from baseline in LDL-C in all subjects and those at TS 1 or $2 over the study duration ( Fig. 3 and Table 2 ). Mean LDL-C levels were reduced by w35% from month 1 in all subject groups, with a further reduction to w45% at month 3. LDL-C levels were then maintained at this level to month 30. At month 36/early termination, the mean reduction in LDL-C in the TS 1 group remained at 243.8%, whereas in the TS $2 group, it decreased to 239.9%.
A total of 52% of subjects aged ,10 years attained the LDL-C target of ,3.35 mmol/L (130 mg/dL) at month 3, and goal attainment remained above 50% for the duration of the study, peaking at 67.4% at month 18. For the age $10 years' cohort, 52% of subjects achieved this goal at month 2, and goal attainment remained above 50% for the duration of the study, peaking at 78% at month 30 (Fig. 4) .
The mean percentage reductions from baseline at month 36/early termination in TC, non-HDL-C, and apoB were comparable for subjects at TS 1 and TS $ 2 ( Fig. 5 and Table 2 ). HDL-C levels decreased slightly (1.1%) from baseline at month 36/early termination in subjects at TS 1 and increased slightly (1.6%) in subjects at TS $ 2. Baseline TG levels were slightly higher in the TS $2 group when compared with the TS 1 group (0.980 vs 0.880 mmol/L [86.8 vs 77.9 mg/dL], respectively). A larger mean percentage reduction in TG level at month 36/early termination was observed in the TS $2 group than in the TS 1 group (27.76% vs 20.70%). A modest reduction in apo-A1 levels was reported for both TS groups (24.80% vs 21.95% for TS 1 and TS $2 at month 36/early termination, respectively).
Flow-mediated dilation
The FMD profile showed no discernable trends in either male or female subjects (See Supplemental Information).
Development and growth
At the month 36/early termination visit, male subjects had increased in height from baseline by a mean of 11.0% vs a mean of 8 termination. At the month 36/early termination, male subjects had increased in weight from baseline by a mean of 32.5% compared with 27.3% for female subjects. The shift in TS over this 3-year study is shown in Figure 6 . By month 36/early termination visit just 41 of 253 subjects (16.2%) were at TS 1 in comparison with 139 of 271 (51.3%) at baseline. Conversely, the percentage of subjects at TS 5 increased from 6.6% (18 of 271) at baseline to 25.3% (64 of 253) at study end.
Safety
The overall incidence of all-causality AEs was very similar in the TS 1 (81.3%) and TS $2 (79.5%) groups (Table 3 ). Most AEs were of mild or moderate intensity. There were no deaths. Overall, 21 patients (7.7%) reported a serious AE (SAE). Overall, 6 (2.2%) subjects discontinued because of AEs (Table 3 ). This included 4 subjects at TS 1 (1 subject experienced Ewing's sarcoma, 1 increase in blood bilirubin, 1 intravascular papillary endothelial hyperplasia, and 1 subject experienced abdominal pain, constipation, fatigue, and headache), and 2 subjects at TS $ 2 (1 subject experienced myalgia and 1 eosinophilia). A total of 24 (8.9%) subjects had their dose reduced or temporarily discontinued because of treatment-related AEs. All the treatment-related AEs were mild or moderate in intensity. The most commonly occurring all-causality AEs are shown in Table 3 .
Of the subjects with a SAE, 14 were from the TS 1 group, and 7 were from the TS $2 group (see Supplemental Information for full details of these SAEs). A single SAE considered to be treatment-related by the investigator was reported: a 9-year-old male receiving atorvastatin 80 mg experienced an SAE of Ewing's sarcoma on day 704 of the study. The subject was hospitalized as a result of this condition. There was no evidence of doserelated increase in the overall incidence of AEs or discontinuations/dose reduction of study medication (Supplemental Tables 2 and 3 ).
There were no obvious trends, or dose-related trends, in the incidence of laboratory abnormalities. No subjects had 
Discussion
This 3-year, open-label, prospective study enrolling very young subjects with HeFH demonstrated that atorvastatin was well tolerated and efficacious in children and adolescents (6-15 years at study entry). Furthermore, there was no evidence that treatment with atorvastatin had any clinically relevant effect on growth or maturation. Because endogenous steroid hormone production is derived from cholesterol, a potential concern is how statin therapy may affect sexual development in children and adolescents. 33 An earlier study demonstrated that treatment with lovastatin (20-40 mg/day) for 24 weeks had no effect on hormone levels or menstrual cycle length in adolescent girls with HeFH aged 10-17 years. 19 The TS shift from baseline during our 3-year trial was consistent with the normal trajectory for maturation and development. For example, movement to TS 2 occurs from age 11 years (range, 8-13 years) in females and slightly later in males (range, 9.5-13.5 years), and TS 5 is usually reached at 14-15 years in females (range, 13-18 years) and 15 years in males (range, 13.5-17 years). 34, 35 Furthermore, the mean height of both male and female subjects was above the 0 z-score lines on the gender-specific WHO height for age charts. 36, 37 The mean height in males followed the 1 z-score line. In both males and females, the mean increase in height over the 3-year study followed the same trajectory as this reference group.
There is increasing evidence that the administration of statins early in life is beneficial in preventing or reducing atherosclerosis in subjects with FH. 8, 38 In this study, we observed that atorvastatin administration led to substantial reductions in LDL-C and other atherogenic lipid parameters. The reductions in LDL-C reached maximal levels of w45% at months 3 to 6 and then remained at this level throughout the follow-up period. There was a slight increase in LDL-C at month 36/early termination, possibly due to the inclusion of data from subjects who discontinued study medication early in the trial. Substantial reductions at month 36/early termination were also observed in apo B and non-HDL-C. There appeared to be no evidence of variations in the lipid-lowering efficacy of atorvastatin between the TS groups analyzed (1 vs $2) or in subjects aged ,10 vs $10 years.
The reductions of LDL-C observed are in accordance with the findings from other clinical studies conducted in pediatric and adolescent populations in which atorvastatin and other statins have been administered. 17, [19] [20] [21] [22] [23] [24] [25] [26] 28 Moreover, the early efficacy of atorvastatin in this study is consistent with that observed in a similar but smaller (n 5 39) short-term (8-week) atorvastatin study in which doses of 5-20 mg per day were administered to children and adolescents with HeFH. In the small 8-week study, mean LDL-C reductions from baseline of 40.7% and 39.7% were observed at week 8 in subjects at TS 1 and $2, respectively. 21 Similar reductions in LDL-C (40%) were observed at week 26 in a larger study (n 5 187) in which atorvastatin (10-20 mg per day) was administered to children and adolescents with FH or severe hypercholesterolemia. 26 The slightly greater reductions in LDL-C observed in this (w45%) vs the earlier studies (w40%) might be related to the higher doses of atorvastatin permitted in this study (up to 80 mg per day).
Atorvastatin was shown in this 3-year study to have a favorable safety and tolerability profile. Only 6 (2.2%) patients discontinued because of AEs. Regarding the SAE of Ewing's sarcoma in a 9-year-old male receiving atorvastatin 80 mg, evidence that this was not associated with statin use comes from a meta-analysis of 26 clinical trials of statin therapy, containing over 170,000 participants, which demonstrated no increase in cancer incidence among subjects receiving statins. 39 Also, the etiology of Ewing's sarcoma suggests that it is very unlikely that the atorvastatin treatment was associated with this cancer.
No unexpected or new safety findings were observed despite 27.3% of the children enrolled being 6-8 years and 51.7% ,10 years at the start of the study. The differences in AEs and treatment-related AEs were not considered to be clinically meaningful, irrespective of TS of the studied subjects. In addition, no clinically meaningful potential safety trends were noted. Moreover, the safety and tolerability profile observed in this study was qualitatively and quantitatively similar to that observed previously in both adult and pediatric populations. 21, 26, 40 The 2013 and 2015 European Atherosclerosis Society consensus statements on FH and the clinical guidance from the National Lipid Association Expert Panel 41 recommend that lipid-lowering therapies should be strongly considered alongside lifestyle changes in children, starting at 8-10 years. 5, 8 This recommendation differs from the 2011 US Integrated Guidelines for the CV Health and Risk Reduction in Children and Adolescents, which notes that children ,10 years should not be treated with lipidlowering medication unless they have LDL-C levels of $400 mg/dL (10.36 mmol/L). 42 This study is limited by its open-label design, lack of an active comparator and by the limited number of subjects who received the 80-mg dose of atorvastatin, which mean our safety data are too limited to draw any conclusions regarding this dose. An additional limitation is the lack of genetic information collated across this cohort of children with HeFH. However, the study has some notable strengths such as children as young as 6 years old being enrolled, a duration of 3 years and the utilization of measures of growth and maturation.
The results of this study suggest that atorvastatin in doses of 5-40 mg is effective and can be used safely in children with HeFH aged as young as 6 years. These findings together with observations from other studies, which have demonstrated that atherosclerotic changes are apparent in children with HeFH before the age of 8 years, 12, 13 and that statins slow this progression, 27, 43 highlight the importance of starting statin therapy early in children with HeFH. 8, [42] [43] [44] Indeed, atorvastatin is now approved for use from 6 years in Australia. 8 In conclusion, our study demonstrates the favorable efficacy, safety, and tolerability profile of atorvastatin in both children as young as 6 years and adolescent subjects, treated for a period of 3 years.
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Results
Flow-mediated dilation
In an effort to measure the effects of low-density lipoprotein cholesterol (LDL-C) lowering on endothelial function, we applied the established method of ultrasonically measured FMD in a part of our study population. A total of 73 subjects (37 at Tanner stage [TS] 1 and 36 at TS stage $2) from four centers were included in the FMD substudy. The FMD profile showed no discernable trends in either male or female subjects with the mean percentage dilation exhibiting little change over the duration of this substudy (Supplemental Fig. 1 ), possibly due to issues both in the methodology and the study design. For example, only a small number of patients took part in this substudy. Also, it is possible that the methodology used varied between the four centers leading to inconsistent results. Finally, the blood vessel walls of the children and adolescents examined may not have been sufficiently thickened by atherosclerosis for a beneficial effect of statins to be observed. Additional studies may be required to evaluate whether treatment with statins can have an effect on FMD in children and adolescents with familial hypercholesterolemia (FH) and whether this technique is useful for measuring endothelial dysfunction and atherosclerosis in children.
Supplemental safety information
The serious adverse events reported by the subjects in the TS 1 group were myositis (this was not associated with abnormal CK values and the subject continued taking study medication), feeling abnormal/syncope, intravascular papillary endothelial hyperplasia, testicular appendage torsion, hemorrhoids, viral infection, appendicitis (2 subjects), bipolar disorder, appendix disorder, concussion, abdominal pain, ulna fracture, and Ewing's sarcoma. The serious adverse events reported by the subjects in the TS $2 group were syncope, limb injury, abdominal pain and vomiting, suicide attempt, lumbar and thoracic vertebral fracture, obesity, and type 1 diabetes mellitus.
Supplemental Figure 1 Mean FMD in a subset of subjects over 36 months among children and adolescents with HeFH receiving atorvastatin therapy. FMD, flow-mediated dilation; HeFH, heterozygous familial hypercholesterolemia. 
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